India could get Covid vaccine for kids, Zydus Cadila set to seek nod for ZyCoV-D
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
India could get Covid vaccine for kids, Zydus Cadila set to seek nod for ZyCoV-D

Coronavirus chronicle

Hindustan Times
05 June, 2021, 12:35 pm
Last modified: 05 June, 2021, 12:54 pm

Related News

  • India considering spending additional $26 billion to fight inflation
  • India cuts excise duty on petrol, diesel; prices to drop by ₹9.5, ₹7 per litre
  • Bangladesh immigrants found guilty in Bengaluru gang rape case
  • Hindu women press for access to Indian mosque, in latest dispute
  • What justifies China’s zero-Covid policy?

India could get Covid vaccine for kids, Zydus Cadila set to seek nod for ZyCoV-D

ZyCov-D, the Zydus' Covid-19 vaccine, is being developed with support from the Centre’s National Biopharma Mission as part of the Biotechnology Industry Research Assistance Council, department of biotechnology.

Hindustan Times
05 June, 2021, 12:35 pm
Last modified: 05 June, 2021, 12:54 pm
NITI Aayog (health) member VK Paul said that not only Bharat Biotech's Covaxin, but Zydus Cadila's vaccine is already being tested on children. (Reuters Photo)
NITI Aayog (health) member VK Paul said that not only Bharat Biotech's Covaxin, but Zydus Cadila's vaccine is already being tested on children. (Reuters Photo)

Zydus Cadila is testing its Covid-19 vaccine candidate on children in the age group of 12-18 years, apart from adults, and the Ahmedabad-based company is likely to apply for licensure of the vaccine in next two weeks, a senior government official has said.

"Not only Covaxin is conducting child trials—and they will not take long because they are all immunogenic trials—but also Zydus vaccine is already being tested on children. So when Zydus comes for licensure, hopefully in the next two weeks, maybe we will also have enough data on the view of whether that vaccine can be given to children," NITI Aayog (health) member VK Paul said during the briefing of the health ministry on Friday.

"We have to understand that the child cohort is not a small cohort. My rough guess is that if it is between 12 to 18 years, this itself is about 13 to 14 crore population and for which we will need about 25-26 crore doses," "We cannot have some people getting and others not getting. So we will have to take this into account when we strategise and make a decision based on how many doses of which vaccines are available," he said.

ZyCov-D, the Zydus vaccine, is being developed with support from the Centre's National Biopharma Mission as part of the Biotechnology Industry Research Assistance Council, department of biotechnology.

Three-dose vaccine

According to the Phase 3 trial protocol submitted to the clinical trial registry of India, the vaccine, which is to be administered intradermally and in three doses, is being tested on 30,000 volunteers.

"The dosing for the Phase III clinical trials has started in 30,000 healthy adult volunteers as part of the multicentric, randomized, double-blind, placebo-controlled, study. ZyCoV-D was found to be safe, well-tolerated and immunogenic in the Adaptive Phase I/II clinical trials," Zydus Cadila has said.

"The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomized, double-blind placebo-controlled study. The vaccine was found to be safe and elicit a strong immunogenic response," it added.

The vaccine is very stable at 2 to 8 degrees as a result in a normal refrigeration temperature, the vaccine is also very thermostable at 25 degrees, the company said.

Next 5-12 years old children

Reports have said that Zydus Cadila is planning to start the trials of ZyCoV-D in children in the age group of 5-12 years after covering adults and 800 children in 12-18 years age group under its ongoing clinical trials.

"We will have a good amount of data on children in this age group. If everything goes well in terms of safety, the vaccine will potentially be approved for use in children aged 12 to 18 years," Cadila Healthcare's managing director Sharvil Patel told the Times of India.

Patel said vaccine development takes place in phases, starting with adults, followed by 12-18 years age group and then for under 12 years children, when asked about plans to test the vaccine for use in children below 12 years age.

Covaxin trials

Patna's All India Institute of Medical Sciences (AIIMS) began the Phase 2/3 clinical trials of Covaxin, developed by the Bharat Biotech International Limited, on children in the age group of 2 to 18 years on Tuesday. As many as 54 children registered at the institute for the trials of which 16 were in the 12-18 years age group.

"We began the children's trials by administering the vaccine on three volunteers in the 12-18 years age group," said Dr Lokesh Tiwari, additional professor and head, department of pediatrics, also one of the investigators in the trials at AIIMS Patna.

"We are commencing the trials today in the reverse order of age from today. Children in the 12 to 18 years age group will be given the shots first. We will then proceed with the 6 to 12 years age category before inoculating children in the 2 to 6 years age bracket," said Dr CM Singh, professor of community and family medicine, also the principal investigator of the trial at AIIMS-Patna and medical superintendent.

According to ANI, AIIMS Delhi is also planning to start the pediatric trials for Bharat Biotech's Covid-19 vaccine, Covaxin, in few days.

Top News

Covid -19 / Zydus Cadila / ZyCoV-D / India

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Collected
    BB cancels foreign trips of private banks, NBFI employees
  • File Photo. Reuters
    Banks to give more 4% interest loans for import substitution crops
  • Photographer: Victor J. Blue/Bloomberg
    Global business is enduring a synchronised slowdown

MOST VIEWED

  • A person in personal protective equipment (PPE) walks a dog at a resident community, as the second stage of a two-stage lockdown has been launched to curb the spread of the coronavirus disease (Covid-19) in Shanghai, China April 3, 2022. REUTERS/Aly Song
    Shanghai reopens some public transport, still on high Covid alert
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Dynamic zero-Covid approach: China's choice to safeguard lives, underpin growth
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine

Related News

  • India considering spending additional $26 billion to fight inflation
  • India cuts excise duty on petrol, diesel; prices to drop by ₹9.5, ₹7 per litre
  • Bangladesh immigrants found guilty in Bengaluru gang rape case
  • Hindu women press for access to Indian mosque, in latest dispute
  • What justifies China’s zero-Covid policy?

Features

Why everybody wants to be like TikTok

Why everybody wants to be like TikTok

6h | Panorama
Illustration: TBS

How the ban on porn sites spawned a local cybersex industry

8h | Panorama
3 best affordable sunscreens for all

3 best affordable sunscreens for all

9h | Mode
Warah uses three types of khadi material: a sheer and light one, a medium count and a thicker one.

Warah: Embroidered with culture and womanhood

11h | Mode

More Videos from TBS

Padma’s Char now largest grazing-ground

Padma’s Char now largest grazing-ground

23m | Videos
Currency depreciation against dollar price hike

Currency depreciation against dollar price hike

23m | Videos
Pran plans to invest in agri sector abroad to keep country's commodity market stable

Pran plans to invest in agri sector abroad to keep country's commodity market stable

28m | Videos
CV or Resume: Which one to create for job application

CV or Resume: Which one to create for job application

10h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab